Compare Illumina, Inc. (ILMN) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Workiva Inc — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Workiva Inc trades at $73.25 (market cap $4.01B). The key difference: Illumina, Inc. is far larger — about 10× Workiva Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Workiva Inc for 21 Days on average.
| ILMN | WK | |
|---|---|---|
Market Cap | $39.95B | $4.01B |
Volume | 3,169,503 | 1,301,708 |
Sector | Health | Technology |
52-Week High | $293.69 | $93.31 |
52-Week Low | $91.00 | $44.31 |
Typical Hold Time | 83 Days | 21 Days |
Enterprise Value | $41.31B | $3.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
Workiva (WK) trades at $73.25, up 2.4% with strong bullish technical signals from moving averages. The company shows improving fundamentals with revenue growth from $885M in 2025 to $966M in 2026 and a shift to profitability with net income of $47M. Recent earnings beats and analyst optimism (16 buy ratings) support the positive momentum, though high valuation ratios (P/E 87.73) suggest premium pricing.
Outlook remains positive with consensus price target of $86 offering 17% upside potential. Key risks include elevated valuation metrics and competitive pressures in the regulatory technology space. The company's AI innovations and inclusion in analyst 'top picks' lists provide growth catalysts, but investors should monitor execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
